We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-2 of 2

Newlink Genetics sets IPO estimates
  • Shook Hardy & Bacon LLP
  • USA
  • November 3 2011

NewLink Genetics Corp., an Iowa biopharmaceutical company focusing on immunotherapeutic products for improved cancer treatment options, has reportedly established the expected range of its initial public offering (IPO) of 5.5 million shares at $10 to $12 a share.